Fas as a Therapeutic Target in Gastrointestinal Stromal Tumors
Author Information
Author(s): Rikhof B, van der Graaf W T A, Meijer C, Le P T K, Meersma G J, de Jong S, Fletcher J A, Suurmeijer A J H
Primary Institution: University Medical Center Groningen, University of Groningen
Hypothesis
Can targeting Fas serve as a therapeutic option for gastrointestinal stromal tumors (GIST)?
Conclusion
Fas is abundantly expressed in GISTs and targeting it with MegaFasL may enhance treatment efficacy, especially in combination with imatinib.
Supporting Evidence
- Fas was expressed in all GISTs and strongly in 93%.
- MegaFasL induced higher levels of apoptosis in GIST cell lines compared to controls.
- Fas and FasL expression were positively correlated in primary GISTs.
Takeaway
This study found that a protein called Fas is found a lot in certain tumors, and using a special treatment called MegaFasL can help kill these tumor cells, especially when used with another medicine called imatinib.
Methodology
The study involved cell line experiments and immunohistochemical evaluations of 45 primary GIST samples to assess Fas and FasL expression.
Limitations
The study primarily focused on in vitro and immunohistochemical analyses, which may not fully represent in vivo responses.
Participant Demographics
{"sex":{"male":19,"female":25},"age":{"median":65.5,"range":"36-87"},"primary_site":{"stomach":29,"small_intestine":12,"colon":3,"unknown":1},"histology":{"spindle_cell":37,"epithelioid":7,"mixed":1}}
Statistical Information
P-Value
0.006
Statistical Significance
p=0.006
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website